Spontaneous and risk period–related VTE in carriers and noncarriers of severe thrombophilia
| Variable . | Carriers . | Noncarriers . |
|---|---|---|
| Subject, n | 70 | 64 |
| Overall VTE | 6 | 0 |
| OAI, 2.09 (95% CI, 0.8-4.5) | OAI, 0 (95% CI, 0-1.4) | |
| Spontaneous VTE | 2 | 0 |
| AI, 0.7 (95% CI, 0.08-2.5) | ||
| Risk period–related VTE | 4 | 0 |
| Incidence for risk period–related VTE, 25% (95% CI, 6.8-64) | ||
| 10 traumas* | ||
| 2 operation | 5 traumas | |
| 2 OCT | 2 operations | |
| 1 CVL | 1 OCT | |
| 1 lung infection | 1 urinary infection |
| Variable . | Carriers . | Noncarriers . |
|---|---|---|
| Subject, n | 70 | 64 |
| Overall VTE | 6 | 0 |
| OAI, 2.09 (95% CI, 0.8-4.5) | OAI, 0 (95% CI, 0-1.4) | |
| Spontaneous VTE | 2 | 0 |
| AI, 0.7 (95% CI, 0.08-2.5) | ||
| Risk period–related VTE | 4 | 0 |
| Incidence for risk period–related VTE, 25% (95% CI, 6.8-64) | ||
| 10 traumas* | ||
| 2 operation | 5 traumas | |
| 2 OCT | 2 operations | |
| 1 CVL | 1 OCT | |
| 1 lung infection | 1 urinary infection |
AI, annual incidence; CVL, central venous line; OAI, overall annual incidence; OCT, oral contraceptive treatment.
One with prophylaxis.